Common Stock, par value $0.01 per share
- Symbol
- IRIX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
IRIDEX Corporation
IRIXNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On June 12, 2026, IRIDEX Corporation (the “Company”) convened and then adjourned, without conducting any business, its 2026 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will reconvene at 8:00 a.m., Pacific Time, on Friday, July 10, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting.…
Company context
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Current securities
Recent company filings
- 4 filingSep 16, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 2, 2026
- 10-Q filingAug 18, 2026
- Results of Operations and Financial ConditionAug 18, 2026
- Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureJul 16, 2026
Registered securities in this filing
IRIDEX CORPORATION · 8-K · Filed 2026-06-18
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On June 12, 2026, IRIDEX Corporation (the “Company”) convened and then adjourned, without conducting any business, its 2026 annual meeting of stockholders (the “Annual Meeting”).
The Annual Meeting will reconvene at 8:00 a.m., Pacific Time, on Friday, July 10, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting. The Annual Meeting will still be held in person at the Company’s principal executive offices located at 1212 Terra Bella Avenue, Mountain View, California 94043.
The record date for stockholders entitled to vote at the Annual Meeting remains April 17, 2026. Proxies previously submitted will be voted at the Annual Meeting unless properly revoked, and the stockholders who have already submitted a proxy or otherwise voted need not take any action.
-2-